Comment from Bayer

Summary: Bayer, a global healthcare and medical products company, supports the FDA's pilot program to use AI for optimizing early-phase clinical trials. They advocate for expanding the program's scope beyond oncology, ensuring global coherence, maintaining human oversight, and establishing clear data quality and evaluation metrics.